Clinical Trials Pipeline & In-Development

Glepaglutide

also known as: ZP1848

Zealand Pharma's long-acting GLP-2 analog for short-bowel syndrome — Phase 3 EASE program completed 2023 with mixed results (primary endpoint not met in EASE-1 under the prespecified analysis, though post-hoc and secondary analyses were positive); regulatory path under review.

A long-acting GLP-2 analog (Zealand Pharma) developed as a twice-weekly SC therapy for short-bowel syndrome — the EASE Phase 3 program completed 2023; EASE-1 missed its primary endpoint of weekly PN reduction under the prespecified analysis, though the open-label extension and secondary endpoints supported sustained effect. Zealand's regulatory path forward remains under review as of this writing.

Mechanism of action

GLP-2 receptor agonism with the same intestinotrophic mechanism as teduglutide — enterocyte proliferation, villous expansion, improved nutrient absorption — but administered less frequently owing to extended half-life.

Primary uses

Short-bowel syndrome (Phase 3 complete)

Typical dosing

10 mg twice weekly (subcutaneous)

EASE Phase 3 used 10 mg SC twice weekly.

Regulatory status

Not approved. Phase 3 EASE program (EASE-1, EASE-2, EASE-3) completed 2023 with mixed primary-endpoint results; regulatory path under Zealand Pharma review.

References

[manufacturer] Zealand Pharma. Press release: EASE-1 Phase 3 topline results, 2023.
[clinicaltrials] ClinicalTrials.gov NCT05022264 (EASE-1) and related EASE program studies.

Related peptides

Teduglutide

FDA-approved GLP-2 analog (Gattex/Revestive, 2012) for short-bowel syndrome — the first disease-modifying treatment for SBS, reducing parenteral nutrition dependence by promoting intestinal mucosal growth.

Apraglutide

Ironwood's weekly GLP-2 analog for short-bowel syndrome — STARS Phase 3 positive (2024), NDA submitted to FDA 2025; potentially the first once-weekly SBS therapy and a meaningful improvement over teduglutide's daily dosing.

Guides & tools

Explore with tools

Glossary → Peptide Comparison → Cost Calculator → Beginner's Guide → All Pipeline peptides →

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.